Literature DB >> 25294243

Cyclooxygenase-2 regulates NLRP3 inflammasome-derived IL-1β production.

Kuo-Feng Hua1, Ju-Ching Chou, Shuk-Man Ka, Yu-Ling Tasi, Ann Chen, Shih-Hsiung Wu, Hsiao-Wen Chiu, Wei-Ting Wong, Yih-Fuh Wang, Change-Ling Tsai, Chen-Lung Ho, Cheng-Hsiu Lin.   

Abstract

The NLR family, pyrin domain-containing 3 (NLRP3) inflammasome is a reactive oxygen species-sensitive multiprotein complex that regulates IL-1β maturation via caspase-1. It also plays an important role in the pathogenesis of inflammation-related disease. Cyclooxygenase-2 (COX-2) is induced by inflammatory stimuli and contributes to the pathogenesis of inflammation-related diseases. However, there is currently little known about the relationship between COX-2 and the NLRP3 inflammasome. Here, we describe a novel role for COX-2 in regulating the activation of the NLRP3 inflammasome. NLRP3 inflammasome-derived IL-1β secretion and pyroptosis in macrophages were reduced by pharmaceutical inhibition or genetic knockdown of COX-2. COX-2 catalyzes the synthesis of prostaglandin E2 and increases IL-1β secretion. Conversely, pharmaceutical inhibition or genetic knockdown of prostaglandin E2 receptor 3 reduced IL-1β secretion. The underlying mechanisms for the COX-2-mediated increase in NLRP3 inflammasome activation were determined to be the following: (1) enhancement of lipopolysaccharide-induced proIL-1β and NLRP3 expression by increasing NF-κB activation and (2) enhancement of the caspase-1 activation by increasing damaged mitochondria, mitochondrial reactive oxygen species production and release of mitochondrial DNA into cytosol. Furthermore, inhibition of COX-2 in mice in vivo with celecoxib reduced serum levels of IL-1β and caspase-1 activity in the spleen and liver in response to lipopolysaccharide (LPS) challenge. These findings provide new insights into how COX-2 regulates the activation of the NLRP3 inflammasome and suggest that it may be a new potential therapeutic target in NLRP3 inflammasome-related diseases.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25294243     DOI: 10.1002/jcp.24815

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  42 in total

Review 1.  Initiation and perpetuation of NLRP3 inflammasome activation and assembly.

Authors:  Eric I Elliott; Fayyaz S Sutterwala
Journal:  Immunol Rev       Date:  2015-05       Impact factor: 12.988

2.  Gamma-tocotrienol attenuates the aberrant lipid mediator production in NLRP3 inflammasome-stimulated macrophages.

Authors:  Yongeun Kim; Anthony D Gromovsky; J Mark Brown; Soonkyu Chung
Journal:  J Nutr Biochem       Date:  2018-06-04       Impact factor: 6.048

Review 3.  Prostaglandin E2 as a Regulator of Immunity to Pathogens.

Authors:  Giovanny J Martínez-Colón; Bethany B Moore
Journal:  Pharmacol Ther       Date:  2017-12-22       Impact factor: 12.310

Review 4.  Targeting the inflammasome in rheumatic diseases.

Authors:  Sara S McCoy; Jasmine Stannard; J Michelle Kahlenberg
Journal:  Transl Res       Date:  2015-06-11       Impact factor: 7.012

5.  Loss of macrophage fatty acid oxidation does not potentiate systemic metabolic dysfunction.

Authors:  Elsie Gonzalez-Hurtado; Jieun Lee; Joseph Choi; Ebru S Selen Alpergin; Samuel L Collins; Maureen R Horton; Michael J Wolfgang
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-02-21       Impact factor: 4.310

Review 6.  Pyroptosis in acute pancreatitis and its therapeutic regulation.

Authors:  Abdullah Al Mamun; Suzia Aktar Suchi; Md Abdul Aziz; Muhammad Zaeem; Fahad Munir; Yanqing Wu; Jian Xiao
Journal:  Apoptosis       Date:  2022-06-10       Impact factor: 5.561

7.  Prostaglandin E2 Inhibits NLRP3 Inflammasome Activation through EP4 Receptor and Intracellular Cyclic AMP in Human Macrophages.

Authors:  Milena Sokolowska; Li-Yuan Chen; Yueqin Liu; Asuncion Martinez-Anton; Hai-Yan Qi; Carolea Logun; Sara Alsaaty; Yong Hwan Park; Daniel L Kastner; Jae Jin Chae; James H Shelhamer
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

8.  Pretreatment of Indobufen and Aspirin and their Combinations with Clopidogrel or Ticagrelor Alleviates Inflammasome Mediated Pyroptosis Via Inhibiting NF-κB/NLRP3 Pathway in Ischemic Stroke.

Authors:  Fengyang Li; Dan Xu; Kai Hou; Xue Gou; Ning Lv; Weirong Fang; Yunman Li
Journal:  J Neuroimmune Pharmacol       Date:  2021-01-29       Impact factor: 4.147

9.  NLRC4 inhibits NLRP3 inflammasome and abrogates effective antifungal CD8+ T cell responses.

Authors:  Camila O S Souza; Natália Ketelut-Carneiro; Cristiane M Milanezi; Lúcia H Faccioli; Luiz G Gardinassi; João S Silva
Journal:  iScience       Date:  2021-05-18

10.  Peripheral-to-central immune communication at the area postrema glial-barrier following bleomycin-induced sterile lung injury in adult rats.

Authors:  David G Litvin; Scott J Denstaedt; Lauren F Borkowski; Nicole L Nichols; Thomas E Dick; Corey B Smith; Frank J Jacono
Journal:  Brain Behav Immun       Date:  2020-02-22       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.